CN1072093A - 硝酸甘油橡皮膏及其制备方法 - Google Patents

硝酸甘油橡皮膏及其制备方法 Download PDF

Info

Publication number
CN1072093A
CN1072093A CN92105694A CN92105694A CN1072093A CN 1072093 A CN1072093 A CN 1072093A CN 92105694 A CN92105694 A CN 92105694A CN 92105694 A CN92105694 A CN 92105694A CN 1072093 A CN1072093 A CN 1072093A
Authority
CN
China
Prior art keywords
weight
nitroglycerin
acrylate
cross
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN92105694A
Other languages
English (en)
Other versions
CN1053591C (zh
Inventor
狄特·布特尼尔
寒宁·诺白尔多夫
汗-米·沃尔夫
莱尼尔·赫夫曼
莱·麦科尼
罗·皮·克来恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lts Roman Special Rabe Kgaa System
UCB Pharmaceuticals Inc
Original Assignee
Lts Roman Trabey Systems Co ltd
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Roman Trabey Systems Co ltd, Schwarz Pharma AG filed Critical Lts Roman Trabey Systems Co ltd
Publication of CN1072093A publication Critical patent/CN1072093A/zh
Application granted granted Critical
Publication of CN1053591C publication Critical patent/CN1053591C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种经皮肤给予硝酸甘油用的皮肤 橡皮膏,除了一层载体膜和一层可撕去的保护膜以 外,由一种以交联丙烯酸酯-醋酸乙烯酯共聚物为基 料并含硝酸甘油的胶粘质组成,其用于聚合的单体混 合物含有21至40%(重量)醋酸乙烯酯、55至70% (重量)丙烯酸C2-8-烷基酯和3至10%(重量)丙烯 酸C2-4-羟基烷基酯,混入常见的交联剂和硝酸甘油 后,再加热除去存在的溶剂使之交联。

Description

本发明涉及一种用于经皮肤给予硝酸甘油的皮肤橡皮膏,由一种载体膜和一种以交联丙烯酸酯共聚物为基料含硝酸甘油的胶粘质组成。该橡皮膏还包括一层保护膜,在使用橡皮膏之前,即将其贴到皮肤上之前将保护膜撕下来。
已经公开了许多用于经皮肤给予硝酸甘油的橡皮膏。例如,DE2135533和DE3315272就描述了多层结构并可控制生物活性物质输出的橡皮膏。按照不同的机理释放硝酸甘油,有的由一种单层贮器通过一种控制膜(DE2135533),有的则通过多层贮器的特别构造(DE3315272)。由于多层皮肤膏由于制造复杂而相当昂贵,人们近年来开发了除载体膜外只由一层拼成的橡皮膏。为了容纳足够量的硝酸甘油,并能够再向皮肤输出足够量的硝酸甘油,人们开发了有不同活性物质容量、活性物质输出和在皮肤的粘附性等性质的各种自贴式胶粘质。作为例子,这里列举GB-A2095108、DE-OS3231400、GB-A2086224、EP-A0062682、EP85903926.5、EP86902978.5、EP0285550.EP0272562、US4608249和DE-PS3200369。按照所用的材料和交联度的不同,这些橡皮膏具有各种不同的硝酸甘油容量和输出能力,并表现出不同的皮肤粘附能力。不同的皮肤承受性同样起重要的作用。有些橡皮膏含有用来提高经表皮传质能力的辅助材料(称为吸收加速剂)。
本发明的任务是制造一种经皮肤给予硝酸甘油的皮肤橡皮膏,其特征在于使用了一种粘合剂,该粘合剂不仅有尽可能高的硝酸甘油容量,而且也有高输出能力,因此对于每天所必需的释放量可保持小的橡皮膏释放面积,并由此使得橡皮膏的成本尽可能低。同时,通过使用特殊的胶粘剂,应该简化制造过程,减低成本并省去添加吸收加速剂。这种配药过程的简化同时可减少皮肤刺激和/或胶粘质中硝酸甘油浓度不可控变化的危险性,这种危险在吸收加速剂由胶粘质渗透进皮肤时可伴随发生。
本发明的用于经皮给予硝酸甘油的皮肤橡皮膏由一层载体薄膜、一层以交联丙烯酸酯-醋酸乙烯酯共聚物为基料的含硝酸甘油的胶粘质和一层通常可撕去的保护膜构成,其特征在于,如下这样制备含硝酸甘油的胶粘质,第一阶段,使由21至40%(重量)醋酸乙烯酯、55至70%(重量)丙烯酸C2-8-烷基酯和3至10%(重量)的丙烯酸C2-4-羟基烷基酯组成的混合物(混合物中为100%(重量)的单体)在一种有机溶剂中进行一种游离基的聚合,然后在第二阶段使一种常见交联剂在一种有机溶剂中和对于所需的橡皮膏用途必要量的硝酸甘油必要时在一种有机溶剂中相混合,最后在第三阶段使得到的混合物及一定的丙烯酸酯-醋酸乙烯酯共聚物在一附加阶段加热交联并除去所加的有机溶剂及溶剂混合物,通过以特殊的方式对特定的丙烯酸酯-醋酸乙烯酯共聚物进行追补和附加交联,使含有的硝酸甘油“装入”胶粘质中。丙烯酸酯-醋酸乙烯酯共聚物的相对粘度为3.0至4.2。
优选使单体混合物除醋酸乙烯酯外还含有2-乙基己基丙烯酸酯和羟基乙基丙烯酸酯。优选使特殊的丙烯酸酯-醋酸乙烯酯共聚物与一种尤其是占共聚物重量0.3至3%(重量)的由聚钛酸丁酯和/或乙酰丙酮化钛组成的钛酸酯进行如下的交联。
制备本发明的橡皮膏工艺的特征在于,将对于橡皮膏所需用途必要量的硝酸甘油和含有一种交联剂或常见混合交联剂的一种由21至40%(重量)醋酸乙烯酯、55至70%(重量)丙烯酸C2-8-烷基酯和3至10%(重量)丙烯酸C2-4-羟基烷基酯组成的单体混合物进行游离基聚合后得到的共聚物的溶液以所需的厚度涂到橡皮膏的保护层上,加热脱去溶剂或混合溶剂,并附加交联这种特殊的丙烯酸酯-醋酸乙烯酯共聚物。
优选方法的特征在于,使丙烯酸酯-醋酸乙烯酯共聚物、硝酸甘油和交联剂溶于一种溶剂中,该溶剂含有20至40%(重量)的乙醇或一种乙醇-甲醇混合物,并有一种40至60%的由特定的丙烯酸酯-醋酸乙烯酯共聚物、交联剂和硝酸甘油组成的混合固体组分。
实施例
本发明经皮肤使用硝酸甘油的皮肤橡皮膏的制备方法,其数量说明以附着面积为100m2为基准。
在强烈混合条件下,向16.00Kg  40%(G/G)的丙烯酸酯-醋酸乙烯酯共聚物溶液中缓慢加入4.00Kg油状形式的硝酸甘油。随后搅拌使混合均匀。在这种胶粘溶液中形成一种20%(G/G)的硝酸甘油溶液。
丙烯酸酯-醋酸乙烯酯共聚物这样制得:
从112g醋酸乙烯酯、270g  2-乙基己基丙烯酸酯、20g羟基乙基丙烯酸酯、1.4g偶氮二异丁腈和407g醋酸乙酯的总量中,向115g醋酸乙酯加入112g醋酸乙烯酯、39g2-乙基己基丙烯酸酯、3g羟基乙基丙烯酸酯和0.5g偶氮二异丁腈,加热至回流。在恒定回流条件下,在4小时时间内加入这些组合的剩余部分。聚合结束后,将混合物冷却至室温。得到的胶粘聚合物溶液在25℃时的粘度为5300mpa.s,用一种Brookfield粘度计测量,溶液的固体组分占47.9%,相比粘度为3.1。
向该溶液中加入1.35乙酰丙酮钛和足量的乙醇或乙醇-醋酸乙酯混合物,以使将产物中的固体含量调节到40%。
例1
将上述含20%(G/G)硝酸甘油的胶粘溶液涂到一层100μm厚的硅酮化的聚酯薄膜上,使其在除去溶剂后得到一层单位面积重量为92g/m2的膜片。用一层19μm厚的聚酯薄膜覆盖该膜片,并冲割成接触面积为16qcm的橡皮膏(图1和2)。一块这样制备的重420mg的皮肤橡皮膏含有55mg硝酸甘油。
为了评价在活体外的活性物质释放性能,将一块冲割面积为3.14qcm的橡皮膏在一个改性的Franz扩散小室内(见Chien,Yie  W.,今日药品23卷,11期(1987)625-646页)固定到无毛鼠的皮肤标本上。
紧接着用18.00ml等张的磷酸盐缓冲液(32±0.5℃)无气泡地浇灌到小室中,并恒温在32±0.5℃。在2,4,6和24小时后,将该释放介质换成新鲜的、恒温到32±0.5℃的溶液。对取出的溶液进行HPLC色谱分析(=高效液相色谱分析)(文献:Pharm.Biol.4,32(1981)),测定其硝酸甘油含量。图3为用这种方法测出的16qcm大的橡皮膏的释放曲线。
平均硝酸甘油释放率(±S.D.)为(n=3):
2小时后  2.32±0.56mg/16qcm
4小时后  4.42±1.00mg/16qcm
6小时后  6.43±1.33mg/16qcm
24小时后  18.74±2.43mg/16qcm
例2
向上述含20%(G/G)硝酸甘油的胶粘溶液再加入0.8%(G/G)乙酰丙酮钛(制造商:Dynamit Nobel(荷兰,B.V.,在异丙醇中形成的75%(G/G)的溶液),以聚丙烯酸酯胶粘溶液中40%(G/G)的固体组分另加硝酸甘油为基准计算,并均化该混合物。将该溶液涂到一层100μm厚的硅酮化聚酯膜上,使得脱除溶剂后得到一层单位面积重量为93g/m2的膜片。用一层19μm厚的聚酯膜覆盖该膜片,并冲割成接触面积为16qcm的橡皮膏(图1和2)。这样制成的一块重量为420mg的皮肤橡皮膏含55mg硝酸甘油。
相应于例1中的方法进行活性物质释放。对应的释放曲线同样在图3中示出。
平均硝酸甘油释放率(±S.D.)为(n=3):
2小时后  0.54±0.20mg/16qcm
4小时后  1.20±0.37mg/16qcm
6小时后  1.78±0.53mg/16qcm
24小时后  6.60±1.56mg/16qcm
例3
将上述含20%(G/G)硝酸甘油的胶粘溶液涂到100μm厚的硅酮化聚酯膜上,除去溶剂后,得到一层单位面积重量为64g/m2的膜片。用一层19μm厚的聚酯膜覆盖该膜片,并冲割成接触面积为16qcm的橡皮膏(图1和2)。这样制成的一块重360mg的皮肤橡皮膏含40mg硝酸甘油。按例1的方法进行活性物质释放。图3同样示出了得到的相应的释放曲线。
平均的硝酸甘油释放率(±S.D.)为(n=3):
2小时后  1.27±0.29mg/16qcm
4小时后  2.48±0.48mg/16qcm
6小时后  3.56±0.60mg/16qcm
24小时后  10.79±0.82mg/16qcm。

Claims (7)

1、一种经皮肤给予硝酸甘油的皮肤橡皮膏的制备方法,橡皮膏由一层载体膜、一层以丙烯酸酯-醋酸乙烯酯共聚物为基料含硝酸甘油的胶粘质和一层用前可撕去的保护膜组成,其特征在于,使一种由21至40%(重量)醋酸乙烯酯、55至70%(重量)丙烯酸C2-8-烷基酯和3至10%(重量)丙烯酸C2-4羟基烷基酯(以所用单体混合物重量为100%)组成的单体混合物在一种有机溶剂中进行游离基聚合,将制得的丙烯酸酯-醋酸乙烯酯共聚物的含对于所需橡皮膏应用必要量硝酸甘油和一种交联剂的溶液以所需的厚度涂到橡皮膏的保护膜上,加热除去溶剂或溶剂混合物,使特定的丙烯酸酯-醋酸乙烯酯进行交联,然后盖上载体膜,并将橡皮膏切成和/或冲割成所需的大小。
2、权利要求1所述的方法,其特征是,丙烯酸C2-4-羟基烷基酯是羟乙基丙烯酸酯。
3、权利要求1或2所述的方法,其特征是,除2-羟基乙基丙烯酸酯以外的丙烯酸C2-8-烷基酯是丙烯酸乙酯。
4、权利要求1至3中任一项所述的方法,其特征是,交联剂是一种钛酸酯或一种钛酸酯混合物。
5、权利要求4所述的方法,其特征是,用0.3至3%(重量)的钛酸酯或钛酸酯混合物进行交联,这些重量百分数是以含交联剂的、通过游离基聚合得到的共聚物的重量为基准计算的。
6、权利要求4和5中之一所述的方法,其特征是,交联剂是乙酰丙酮钛和/或聚钛酸丁酯。
7、权利要求1至6中一或多项所述的方法,其特征是,使特定的丙烯酸酯-醋酸乙烯酯共聚物、硝酸甘油和交联剂共同溶于一种溶剂混合物中,该混合物含有20至40%(重量)乙醇或乙醇-甲醇混合物,其由特定丙烯酸酯-醋酸乙烯酯共聚物、交联剂和硝酸甘油组成的固体组分占40至60%(重量)。
CN92105694A 1991-06-10 1992-06-09 硝酸甘油橡皮膏的制备方法 Expired - Lifetime CN1053591C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4118891.8 1991-06-10
DE4118891 1991-06-10

Publications (2)

Publication Number Publication Date
CN1072093A true CN1072093A (zh) 1993-05-19
CN1053591C CN1053591C (zh) 2000-06-21

Family

ID=6433497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92105694A Expired - Lifetime CN1053591C (zh) 1991-06-10 1992-06-09 硝酸甘油橡皮膏的制备方法

Country Status (18)

Country Link
US (1) US5498418A (zh)
EP (2) EP0588839B1 (zh)
JP (1) JP2579729B2 (zh)
KR (1) KR0165875B1 (zh)
CN (1) CN1053591C (zh)
AT (1) ATE126434T1 (zh)
CA (1) CA2109956C (zh)
DE (1) DE59203307D1 (zh)
DK (1) DK0588839T3 (zh)
ES (1) ES2077419T3 (zh)
FI (1) FI101854B (zh)
GE (1) GEP19991583B (zh)
GR (1) GR3017689T3 (zh)
HU (1) HU210334B (zh)
IE (1) IE67792B1 (zh)
NO (2) NO305384B1 (zh)
UA (1) UA29400C2 (zh)
WO (1) WO1992022292A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1070367C (zh) * 1997-08-07 2001-09-05 德阳华康药业有限公司 注射贴及其制备方法
CN101291962B (zh) * 2005-09-23 2012-06-20 汉高股份两合公司 丙烯酸类聚合物基粘合剂
CN105362254A (zh) * 2015-12-09 2016-03-02 北京邦尼康达医药科技有限公司 一种硝酸甘油贴膜及其制备方法
CN106659591A (zh) * 2014-08-25 2017-05-10 汉高知识产权控股有限责任公司 丙烯酸聚合物和它们在透皮药物递送中的用途
CN113125596A (zh) * 2021-04-07 2021-07-16 马应龙药业集团股份有限公司 一种高效液相色谱法测定硝酸甘油软膏中有关物质的方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
DE4406332C1 (de) * 1994-02-28 1995-06-22 Sanol Arznei Schwarz Gmbh Pharmazeutische Verwendung von Nitroglycerin zur Verhinderung unerwünschter Wehentätigkeit bei Säugern in einer transdermalen Applikationsform
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
WO1998025591A1 (en) * 1996-12-10 1998-06-18 Rotta Research B.V. Transdermal drug delivery system for the treatment of heart diseases
ES2127711T1 (es) * 1996-12-10 1999-05-01 Rotta Res Bv Sistema de administracion transdermal de farmacos para el tratamiento de enfermedades del corazon.
DE19818955C2 (de) * 1998-04-28 2000-06-29 Lohmann Therapie Syst Lts Zusammensetzung, enthaltend Polyacrylat, Polyterpen, Nitroglycerin und wahlweise Polyvinylacetat
DE19830648A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Glyceroltrinitrathaltige Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19831418C2 (de) * 1998-07-14 2000-07-06 Lohmann Therapie Syst Lts Verfahren und Vorrichtung zum Herstellen flächenhafter Produkte aus Laminat, deren Übertragung auf eine Abdeckfolie und Endkonfektionierung
TR200101790T2 (tr) 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
JP5021124B2 (ja) * 2001-08-29 2012-09-05 日東電工株式会社 医療用粘着組成物、それを用いた医療用粘着テープおよび経皮吸収用テープ製剤
EP1293198B1 (en) * 2001-09-14 2005-02-09 Schwarz Pharma Ag Device for transdermal administration for the treatment of urinary tract disorders
CN1655772B (zh) * 2002-05-28 2010-05-26 拉伯泰克技术研发有限公司 含有芬太尼的贴剂
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
KR100563194B1 (ko) * 2003-11-14 2006-03-21 (주) 에프디엘 펜타닐을 유효성분으로 함유하는 경피투여제제
WO2006050926A2 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US20070072987A1 (en) * 2005-09-23 2007-03-29 Allison Luciano Acrylic polymer-based adhesives
DE202016007127U1 (de) 2016-11-22 2016-12-19 Ludwig Volker Falzhilfe

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
JPS5843368B2 (ja) 1980-10-30 1983-09-27 日東電工株式会社 消炎鎮痛貼付剤
JPS57116011A (en) 1981-01-08 1982-07-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
JPS6059207B2 (ja) 1981-03-13 1985-12-24 日東電工株式会社 複合製剤の製法
GB2105990B (en) 1981-08-27 1985-06-19 Nitto Electric Ind Co Adhesive skin patches
US4608249A (en) 1982-11-02 1986-08-26 Nitto Electric Industrial Co., Ltd. Hydrophilic therapeutic material
DE3315272C2 (de) 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
EP0190262B1 (en) 1984-07-24 1990-12-27 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
JPS62292877A (ja) * 1986-06-13 1987-12-19 Nippon Shokubai Kagaku Kogyo Co Ltd 接着剤用組成物
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
JPH0696529B2 (ja) * 1987-03-31 1994-11-30 積水化学工業株式会社 ニトログリセリン貼付剤およびその製造方法
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
JP2524190B2 (ja) * 1988-05-11 1996-08-14 日東電工株式会社 クロニジンを含有する粘着テ―プ製剤
JP2970772B2 (ja) * 1989-12-28 1999-11-02 日東電工株式会社 経皮吸収ゲル製剤
EP0435199B2 (en) * 1989-12-28 2000-01-19 Nitto Denko Corporation Acrylic gel material and acrylic gel preparation
JP2882843B2 (ja) * 1990-03-28 1999-04-12 日本化薬株式会社 門脈圧亢進症改善剤
JPH07116032B2 (ja) * 1990-04-06 1995-12-13 積水化学工業株式会社 ニトログリセリン貼付剤

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1070367C (zh) * 1997-08-07 2001-09-05 德阳华康药业有限公司 注射贴及其制备方法
CN101291962B (zh) * 2005-09-23 2012-06-20 汉高股份两合公司 丙烯酸类聚合物基粘合剂
CN106659591A (zh) * 2014-08-25 2017-05-10 汉高知识产权控股有限责任公司 丙烯酸聚合物和它们在透皮药物递送中的用途
CN106659591B (zh) * 2014-08-25 2021-06-04 汉高知识产权控股有限责任公司 丙烯酸聚合物和它们在透皮药物递送中的用途
CN105362254A (zh) * 2015-12-09 2016-03-02 北京邦尼康达医药科技有限公司 一种硝酸甘油贴膜及其制备方法
CN113125596A (zh) * 2021-04-07 2021-07-16 马应龙药业集团股份有限公司 一种高效液相色谱法测定硝酸甘油软膏中有关物质的方法
CN113125596B (zh) * 2021-04-07 2023-01-13 马应龙药业集团股份有限公司 一种高效液相色谱法测定硝酸甘油软膏中有关物质的方法

Also Published As

Publication number Publication date
IE67792B1 (en) 1996-04-17
KR0165875B1 (ko) 1999-01-15
HU210334B (en) 1995-03-28
CA2109956A1 (en) 1992-12-23
EP0518113A1 (de) 1992-12-16
CN1053591C (zh) 2000-06-21
NO934518D0 (no) 1993-12-09
ES2077419T3 (es) 1995-11-16
CA2109956C (en) 1998-05-05
GEP19991583B (en) 1999-04-29
UA29400C2 (uk) 2000-11-15
JPH06506944A (ja) 1994-08-04
FI101854B1 (fi) 1998-09-15
FI935522A (fi) 1993-12-09
HUT65979A (en) 1994-08-29
IE921863A1 (en) 1992-12-16
DK0588839T3 (da) 1995-12-27
EP0588839A1 (de) 1994-03-30
FI101854B (fi) 1998-09-15
JP2579729B2 (ja) 1997-02-12
WO1992022292A1 (de) 1992-12-23
HU9303532D0 (en) 1994-04-28
GR3017689T3 (en) 1996-01-31
FI935522A0 (fi) 1993-12-09
US5498418A (en) 1996-03-12
DE59203307D1 (de) 1995-09-21
NO934518L (no) 1993-12-09
EP0588839B1 (de) 1995-08-16
NO305384B1 (no) 1999-05-25
ATE126434T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
CN1053591C (zh) 硝酸甘油橡皮膏的制备方法
EP1163902B1 (en) Transdermal preparation containing hydrophilic or salt-form drug
US5242951A (en) Estrogen-containing gel preparation
JP5155900B2 (ja) 架橋型皮膚用粘着剤
US5368860A (en) Preparation for transdermal drug administration
JP2000514695A (ja) エストラジオールおよび他のステロイドを同時投与するための経皮薬物送達マトリックス
JP2002510617A (ja) ジクロフェナクの経皮送達用デバイス
JP4272636B2 (ja) 架橋型皮膚用粘着剤
EP0777468B1 (de) Medizinischer haftkleber
AU727257B2 (en) Transdermal or topical plaster system with a polyacrylate matrix with improved physical properties
JP4466977B2 (ja) 経皮的治療システム
CN1309377C (zh) 含有至少一种可影响血液中脂质浓度的活性物质的透皮贴片
CA2033109C (en) Acrylic gel material and acrylic gel preparation
JP2967788B2 (ja) 医療用粘着テープおよび疾患治療用テープ製剤
JP4394071B2 (ja) 経皮吸収製剤用粘着剤、経皮吸収用粘着剤組成物及び経皮吸収製剤
WO2004108112A1 (ja) 皮膚外用剤用粘着剤組成物および皮膚外用剤粘着シート
EP0436203B1 (en) Percutaneous gel preparation
JPS597687B2 (ja) 医薬部材
JPH0339488B2 (zh)
CN100548302C (zh) 含有雌性激素的贴剂
JP3176400B2 (ja) 薬物の表皮細胞層透過促進剤および経皮吸収製剤
JPH0137375B2 (zh)
JPS5823846B2 (ja) 親水性医薬部材
JP4617069B2 (ja) 貼付剤
JP2021084041A (ja) 非イオン性界面活性剤、皮膚貼付用粘着剤、皮膚貼付剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C56 Change in the name or address of the patentee

Owner name: UCB PHARMA INC.

Free format text: FORMER NAME: SCHWARZ PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: The Federal Republic of Germany, the Mongolian mother of the sea

Co-patentee after: LTS Roman special Rabe KGaA system

Patentee after: UCB Pharma Inc.

Address before: The Federal Republic of Germany, the Mongolian mother of the sea

Co-patentee before: LTS Roman special Rabe KGaA system

Patentee before: Schwarz Pharma AG

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20120609

Granted publication date: 20000621